Boston Scientific ((BSX)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Boston Scientific is currently recruiting for a study titled ‘Deep Brain Stimulation (DBS) Retrospective Outcomes Study.’ The primary aim is to assess real-world clinical outcomes of DBS by reviewing de-identified patient records. This study is significant as it focuses on understanding the effectiveness of DBS in treating conditions like Parkinson’s Disease, Essential Tremor, and Dystonia.
The intervention being tested is the Deep Brain Stimulation device, which is designed to improve symptoms in patients suffering from neurological disorders such as Parkinson’s Disease, Essential Tremor, and Dystonia.
This is an observational study with a retrospective time perspective. It involves analyzing existing data from patients who have already been implanted with the DBS system, without any new allocation or intervention model being applied.
The study began on August 31, 2018, with the latest update submitted on October 13, 2025. These dates are crucial as they indicate the ongoing nature of the study and its progress over time.
For investors, the continuation of this study could positively influence Boston Scientific’s stock performance by demonstrating the effectiveness of their DBS system, potentially increasing market share in the neurological device sector. Competitors in the medical device industry will be closely monitoring these developments.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.